| Identification | Back Directory | [Name]
2-Furancarboxamide, 5-nitro-N-[4-[7-(1,2,3,6-tetrahydro-4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]- | [CAS]
2740522-79-4 | [Synonyms]
W1131
2-Furancarboxamide, 5-nitro-N-[4-[7-(1,2,3,6-tetrahydro-4-pyridinyl)imidazo[1,2-a]pyridin-3-yl]phenyl]- | [Molecular Formula]
C23H19N5O4 | [MOL File]
2740522-79-4.mol | [Molecular Weight]
429.43 |
| Chemical Properties | Back Directory | [density ]
1.46±0.1 g/cm3(Predicted) | [solubility ]
DMSO: Slightly soluble: 0.1-1 mg/ml | [form ]
Solid | [pka]
11.58±0.70(Predicted) | [color ]
Yellow to orange |
| Hazard Information | Back Directory | [Uses]
W1131 is a potent STAT3 inhibitor, triggering ferroptosis. W1131 suppresses cancer progression in gastric cancer cell subcutaneous xenograft model, organoids model, and PDX model. W1131 effectively alleviates chemical resistance of cancer cells to 5-FU (HY-90006). W1131 regulates cell cycle, DNA damage response, and oxidative phosphorylation, including IL6-JAK-STAT3 pathway and ferroptosis pathway[1]. | [in vivo]
W1131 (3 mg/kg, 10 mg/kg; i.p.; once daily for 2 weeks) inhibits tumor growth dose-dependently, and induces ferroptosis in MGC803 subcutaneous xenograft model in BALB/c-nu/nu mice[1].
| Animal Model: | MGC803 subcutaneous xenografts in mouse[1] | | Dosage: | 3 mg/kg, 10 mg/kg | | Administration: | Intraperitoneal injection; once daily for 2 weeks | | Result: | Inhibited GPX4, SLC7A11, and FTH1 expression level, indicating the induction of ferroptosis.
Caused insignificant change of body weight. |
| [References]
[1] Ouyang S, et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol. 2022 Jun;52:102317. DOI:10.1016/j.redox.2022.102317 |
|
|